We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

133 hedge funds and large institutions have $385M invested in Progenics Pharmaceuticals Inc in 2015 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 43 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

29% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $886K

10% more funds holding

Funds holding: 121133 (+12)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 43

23% less capital invested

Capital invested by funds: $501M → $385M (-$116M)

Holders
133
Holders Change
+12
Holders Change %
+9.92%
% of All Funds
3.71%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
43
Reduced
43
Closed
12
Calls
$1.14M
Puts
$886K
Net Calls
+$254K
Net Calls Change
-$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
Swiss National Bank
51
Swiss National Bank
Switzerland
$541K +$89.8K +11,700 +14%
WMSA
52
Weiss Multi-Strategy Advisers
New York
$521K +$7.67K +1,000 +1%
Citadel Advisors
53
Citadel Advisors
Florida
$507K +$133K +17,269 +24%
AQR Capital Management
54
AQR Capital Management
Connecticut
$480K -$119K -15,533 -16%
Fisher Asset Management
55
Fisher Asset Management
Washington
$476K +$639K +83,250 New
SAMC
56
Shinko Asset Management Company
Japan
$476K +$639K +83,250 New
Citigroup
57
Citigroup
New York
$470K +$471K +61,442 +296%
SC
58
Searle & Co
Connecticut
$429K -$19.2K -2,500 -3%
AI
59
Analytic Investors
California
$427K +$573K +74,615 New
CCMH
60
Cornerstone Capital Management Holdings
New York
$415K +$401K +52,200 +257%
HK
61
Horizon Kinetics
New York
$384K
RhumbLine Advisers
62
RhumbLine Advisers
Massachusetts
$370K +$17.8K +2,322 +4%
TC
63
TFS Capital
Pennsylvania
$363K -$1.84M -239,232 -79%
ProShare Advisors
64
ProShare Advisors
Maryland
$342K -$35.6K -4,641 -7%
CHAM
65
Clear Harbor Asset Management
Connecticut
$330K -$921 -120 -0.2%
CS
66
Credit Suisse
Switzerland
$306K -$1.84M -239,308 -82%
SAM
67
Symphony Asset Management
California
$295K +$128K +16,739 +48%
HCM
68
Hollencrest Capital Management
California
$286K
HCM
69
Highbridge Capital Management
New York
$277K +$372K +48,429 New
T. Rowe Price Associates
70
T. Rowe Price Associates
Maryland
$272K +$62.2K +8,100 +21%
IAM
71
Integre Asset Management
New York
$271K +$363K +47,319 New
MLICM
72
Metropolitan Life Insurance Company (MetLife)
New York
$259K -$29.4K -3,837 -8%
NFA
73
Nationwide Fund Advisors
Ohio
$259K
State Board of Administration of Florida Retirement System
74
State Board of Administration of Florida Retirement System
Florida
$259K
EGA
75
Eagle Global Advisors
Texas
$257K -$172K -22,400 -33%

PGNX Hedge Fund Activity: Q3 2015 in Review

133 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2015, worth a combined $385M — down 23% from $501M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PGNX positions and 12 closed out — a net gain of 12 holders — while 43 added to existing stakes and 43 trimmed.

The largest buyer was Bogle Investment Management, opening a new position worth an estimated $6.06M. The largest seller was Wellington Management Group, cutting an estimated $6.12M.

  • 133 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2015, up from 121 in Q2 2015.
  • Funds reported $385M of Progenics Pharmaceuticals Inc stock for Q3 2015, down 23% quarter-over-quarter.
  • 24 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2015 and 12 closed out, a net change of +12 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2015 was Bogle Investment Management, an estimated $6.06M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2015 was Wellington Management Group, an estimated $6.12M sold.

Based on aggregated 13F filings for Q3 2015.